Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma

Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma

Abstract Background Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 have demonstrated promising efficacy in treating refractory or relapsed B-cell malignancies. Nonetheless, challenges such as antigen escape-mediated relapse and toxicities, including cytokine release syndrome (CRS) a...

Full description

Saved in:
Bibliographic Details
Main Authors: Hanyu Wang, Gaoxiang Wang, Tongjuan Li, Peiling Zhang, Zekai Mao, Hui Luo, Xiaojian Zhu, Dengju Li, Jianfeng Zhou, Xiaoxi Zhou, Liang Huang
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Journal of Translational Medicine
Online Access:https://doi.org/10.1186/s12967-025-06567-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-025-06567-3

Similar Items